Current situation and prospect of immunotherapy for advanced renal cell carcinoma
10.3760/cma.j.cn115355-20231120-00195
- VernacularTitle:晚期肾细胞癌免疫疗法的现状及展望
- Author:
Fang LI
1
;
Hongying PENG
Author Information
1. 贵州医科大学附属医院肾内科，贵阳 550004
- Keywords:
Carcinoma, renal cell;
Tumor microenvironment;
Immune checkpoint inhibitors;
Molecular targeted therapy;
Cell therapy
- From:
Cancer Research and Clinic
2024;36(6):477-480
- CountryChina
- Language:Chinese
-
Abstract:
Renal cell carcinoma is a common malignant tumor in urinary system with poor prognosis, and the advanced patients are prone to distant metastases such as bone, brain and lung. Common treatment modalities for renal cell carcinoma include surgery, radiotherapy, immunotherapy and targeted therapy. Tumor microenvironment plays an important role in the occurrence, pathophysiological process and treatment of renal cell carcinoma. The study of tumor microenvironment characteristics has led to significant advances in the treatment of renal cell carcinoma. At present, immunotherapy and cell therapy for renal cancer can effectively prolong the survival of patients and provide new treatment methods for patients with advanced renal cell carcinoma.
